A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

@article{Plank2005ADR,
  title={A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.},
  author={Johannes Plank and Manfred Bodenlenz and Frank Sinner and Christoph Magnes and Evelyn G{\"o}rzer and Werner Regittnig and Lars A. Endahl and Eberhard Draeger and Milan Zdravkovic and Thomas R. Pieber},
  journal={Diabetes care},
  year={2005},
  volume={28 5},
  pages={1107-12}
}
OBJECTIVE To investigate the pharmacodynamic profile and duration of action for five subcutaneous doses of insulin detemir (0.1, 0.2, 0.4, 0.8, and 1.6 units/kg; 1 unit = 24 nmol) and one subcutaneous dose of NPH insulin (0.3 IU/kg; 1 IU = 6 nmol). RESEARCH DESIGN AND METHODS This single-center, randomized, double-blind, six-period, crossover study was carried out as a 24-h isoglycemic clamp (7.2 mmol/l) in 12 type 1 diabetic patients. RESULTS Duration of action for insulin detemir was dose… CONTINUE READING